A phase I, randomized, controlled, dose-ranging study of investigational acellular pertussis (aP) and reduced tetanus-diphtheria-acellular pertussis (TdaP) booster vaccines in adults

Geert Leroux-Roels, Maria Lattanzi, Claudia Dovali Solis, Mario Contorni, Marco Costantini, Luca Moraschini, Monia Bardelli, Sylvie Bertholet, Erica Borgogni, Francesca Buricchi, Rocco Cantisani, Elisa Faenzi, Oretta Finco, Rosanna Leuzzi, Mariagrazia Pizza, Domenico Rosa, Francesca Schiavetti, Anja Seubert, Fabiana Spensieri, Gianfranco Volpini, Luisanna Zedda, Giuseppe Del Giudice, Ilaria Galgani
  • Human Vaccines & Immunotherapeutics, November 2017, Taylor & Francis
  • DOI: 10.1080/21645515.2017.1385686
The author haven't finished explaining this publicationThe author haven't finished explaining this publication

The following have contributed to this page: Professor Geert Leroux-Roels and Dr Sylvie Bertholet